SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50164/005002
	Serial No.	Not Yet Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant	Borisy et al.
	Filing Date	October 2, 2003
	Group	Not Yet Assigned
(37 C.F.R. § 1.98(b))	IDS Filed	October 2, 2003
	Customer Number	21559

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
	5,770,585	06/23/98	Kaufman, et al.	514	78	05/08/95
	6,280,768	08/28/01	McDevitt	424	464	07/01/97

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 01/35935	05/25/01	PCT	31	155	
	1,288,376	09/06/72	Great Britain	123	00	

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

	Al-Abdely et al., "Efficacies of KY62 Against *Leishmania Amazonensis* and *Leishmania donovani* in Experimental Murine Cutaneous Leishmaniasis and Visceral Leishmaniasis", *Antimicrob. Agents Chemother.* 42:2542-2548 (1998) .
	Anees et al., "Inhibition of a Tumor Protease with 3,4-Dichloroisocoumarin, Pentamidine-Isethionate and Guanidino Derivatives", *J. Enzyme Inhibition*, 8:213-221, (1994).
	Bailly et al., "Sequence-Specific DNA Minor Groove Binders. Design and Synthesis of Netropsin and Distamycin Analogues", *Bioconjug. Chem.*, 9:513-538 (1998).
	Bailly et al., "Sequence-Selective Binding to DNA of Bis(Amidinophenoxy)Alkanes Related to Propamidine and Pentamidine", *Biochem J.*, 323:23-31, (1997).
	Barrett et al., "Anti-Sleeping Sickness Drugs and Cancer Chemotherapy", *Parasitology Today*, 16:7-9, (2000).
	Bell et al., "Structure-Activity Relationships of Pentamidine Analogs Against *Giardia lamblia* and Correlation of Antigiardial Activity with DNA-Binding Affinity", *Antimicrob. Agents Chemother.* 35:1099-1107 (1991).
	Benaim et al, "A Calmodulin-Stimulated Ca2+ Pump in Plasma-Membrane Vesicles from *Trypanosoma brucei*; Selective Inhibition by Pentamidine", *Biochem. J*, 296:759-763 (1993).
	Bornstein et al., "An Evalution of the Mechanism of Action of Pentamidine Isethionate", *Journal of Surgical Oncology*, 2:393-398, (1970).
	Budavari et al., *The Merck Index*, 11:1128 (1989).
	Capece et al., "Pharmacokinetic Behaviour of Albendazole Sulphoxide Enantiomers in Male and Female Sheep", *Vet. Res. Commun.* 24:339-348 (2000).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50164/005002
	Serial No.	Not Yet Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant	Borisy et al.
	Filing Date	October 2, 2003
	Group	Not Yet Assigned
(37 C.F.R. §1.98(b))	IDS Filed	October 2, 2003
	Customer Number	21559

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
	Chen et al., "Anti-Tumor Necrosis Factor Properties of Non-Peptide Drugs in Acute-Phase Responses", *Eur. J. Pharmacol* 271:319-327 (1994).
	Chiap et al., "Determination of Albendazole and its Main Metabolites in Ovine Plasma by Liquid Chromatography with Dialysis as an Integrated Sample Preparation Technique", *J. Chromatogr. A*, 870:121-34 (2000).
	Corsini et al., "Induction of Tumor Necrosis Factor-Alpha In Vivo by a Skin Irritant, Tributytin, Through Activation of Transcription Factors: Its Pharmacological Modulation by Anti-Inflammatory Drugs", *J. Invest. Dermatol.* 108: 892-896 (1997).
	Cresson et al., "In Vitro Inhibition of Human Sarcoma Cells' Invasive Ability by Bis(5-Amidino-2-Benzimidazolyl) Methane-a novel esteroprotease inhibitor", *Am. J. Pathol.* 123:46-56, (1986).
	Cubria et al., "Aromatic Diamidines are Reversible Inhibitors of Porcine Kidney Diamine Oxidase", *Biochem. Pharmacol.* 45:1355-1357 (1993).
	Dautzenberg et al., "Pentamidine Aerosol in the Preventive Treatment of Pneumocystosis in AIDS Patients. Comparison of Two Salts and Two Nebulizers", *Presse Med.* 20:1117-1120 (1991).
	Del Poeta et al., "Structure-In Vitro Activity Relationships of Pentamidine Analogues and Dication-Substituted Bis-Benzimidazoles as New Antifungal Agents", *Antimicrob. Agents Chemother.* 42:2495-2502 (1998).
	Ferroni et al., "N1-Substituted Benzamidines: Synthesis, Antiproteinase Activity and Inhibition of Tumor Cell Growth", *Il Farmaco*, 46:1311-1321, (1991).
	Fibach et al., "Phorbol Ester-Induced Adhesion of Murine Erythroleukemia Cells: Possible Involvement of Cellular Proteases", *Carcinogenesis*, 4:1395-1399, (1983).
	Fimognari et al., "Flow Cytometric Analysis of Genetic Damage, Effect on Cell Cycle Progression, and Apoptosis by Thiophanate-Methyl in Human Lymphocytes", *Environ. Mol. Mutagen.* 33:173-176 (1999).
	Fraser et al., "Endo-Exonuclease of Human Leukaemic Cells: Evidence for a Role in Apoptosis", *J. Cell Sci.*, 109:2343-2360, (1996).
	Gambari et al., "DNA-Binding Activity and Biological Effects of Aromatic Polyamidines", *Biochem Pharmacol*, 47:599-610, (1994).
	Gupta, "Cross-Resistance of Nocodazole-Resistant Mutants of CHO Cells Toward Other Microtubule Inhibitors:Similar Mode of Action of Benzimidizole Carbamate Derivatives and NSC 181928 and TN-16", *Mol. Pharmacol.* 30:142-148 (1986).
	Herberich et al., "Synthesis of a Netropsin Conjugate of a Water-Soluble *epi*-Quinocarcin Analogue: the Importance of Stereochemistry at Nitrogen", *Bioorganic & Medicinal Chemistry* 8:523-532 (2000).

EXAMINER	DATE CONSIDERED 8-9-04

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50164/005002
	Serial No.	Not Yet Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant	Borisy et al.
	Filing Date	October 2, 2003
	Group	Not Yet Assigned
(37 C.F.R. §1.98(b))	IDS Filed	October 2, 2003
	Customer Number	21559

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
CM	Hung et al., "Understanding and Controlling the Cell Cycle with Natural Products", *Chemistry & Biology*, 3:623-639 (1996).
	Ingold et al., "Efficacies of Albendazole Sulfoxide and Albendazole Sulfone Against In Vitro-Cultivated *Echinococcus Multilocularis* Metacestodes", *Antimicrob. Agents Chemother.* 43:1052-1061 (1999).
	Kim et al., "Effects of Calmodulin Antagonists and Anesthetics on the Skin Lesions Induced by 2-Chloroethylethyl Sulfide", *Eur. J. Pharmacol.* 313:107-114 (1996).
	Kitamura et al., "Inhibition of Constitutive Nitric Oxide Synthase in the Brain by Pentamidine, a Calmodulin Antagonist", *Eur. J. Pharmacol.* 289:299-304 (1995).
	Klemes et al., "Inhibition of Phorbol-Ester-Induced Adhesion of Differentiating Human Myeloid Leukemic Cells by Pentamidine-Isethionate", *Differentiation*, 27:141-145, (1984).
	Kopac, M.J., "Section of Biology", *The New York Academy of Sciences*, 5-10, (1945).
	Kopac, M.J., "Some Cellular and Surface Chemical Aspects of Tumor Chemotherapy", in Approaches to Tumor Chemotherapy ed. F.R. Moulton, *AAAS*, Washington, D.C. (1947).
	Libby et al., "Inhibition of Enzymes of Polyamine Back-Conversion by Pentamidine and Berenil", *Biochemical Pharmacology*, 44:830-832, (1992).
	Luck et al., "Interaction of Nonintercalative Antitumour Drugs SN-6999 and SN-18071 with DNA: Influence of Ligand Structure on the Binding Specificity", *Journal of Biomolecular Structure & Dynamics* 4:1079-1094, (1987).
	Marques et al., "Enantioselective Kinetic Disposition of Albendazole Sulfoxide in Patients with Neurocysticercosis", *Chirality* 11:218-223 (1999).
	Mesa-Valle et al., "In Vitro Action of Platinum (II) and Platinum (IV) Complexes on *Trypanosoma cruzi* and *Leishmania donovani*", *Arzneimittelforschung* 39:838-842 (1989).
	Mesa-Valle et al., "In Vitro and In Vivo Activity of Two Pt(IV) Salts Against *Leishmania donovani*", *Pharmacology*, 57:160-172 (1998).
	Mesa-Valle CM et al., "Action of New Organometallic Complexes Against *Leishmania donovani*", *J. Antimicrob. Chemother.* 40:47-57 (1997).
	Mongiardo et al., "Pentamidine Salts" *Lancet* 2:108 (1989).
	Morgan et al, "Activities of Several Benzimidazoles and Tubulin Inhibitors Against *Giardia spp. In Vitro*", *Antimicrob. Agents Chemother.* 37:328-331 (1993).
	Nastruzzi et al., "Inhibition of 'In Vitro' Tumor Cell Growth by Aromatic Polyamidines Exhibiting Antiproteinase Activity", *Clin. Expl. Metastasis*, 7:25-39, (1989).
	Nastruzzi et al., "Differential Effects of Benzamidine Derivatives on the Expression of C-MYC and HLA-DRα Genes in a Human B-Lymphoid Tumor Cell Line", *Cancer Letters*, 38:297-305, (1988).

EXAMINER CM	DATE CONSIDERED 8-9-04

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		
	Attorney Docket No.	50164/005002
	Serial No.	Not Yet Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant	Borisy et al.
	Filing Date	October 2, 2003
	Group	Not Yet Assigned
(37 C.F.R. §1.98(b))	IDS Filed	October 2, 2003
	Customer Number	21559

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
CM	National Cancer Institute Developmental Therapeutics Program In-Vitro Testing Results, NSC 620107 Experiment ID 9407SR53-57, (1994).
	Navas et al., "Structural Determinants of Putrescine Uptake Inhibition Produced by Cationic Diamidines in the Model of Trypanosomatid Crithidia Fasciculata", *Biol. Chem*, 377:833-836 (1996).
	Nishimura et al., "A Serine Protease-Inhibitory Benzamidine Derivative Inhibits the Growth of Human Colon Carcinoma Cells", *Jpn. J. Cancer Res.*, 83:723-728, (1992).
	Nunn et al., "Sequence-Dependent Drug Binding to the Minor Groove of DNA: Crystal Structure of the DNA Dodecamer d(CGCAAATTTGCG)$_2$ Complexed with Propamidine", *J. Med. Chem.* 38:2317-2325 (1995).
	Osei et al., "Diabetogenic Effect of Pentamidine", *Am. J. Med.*, 77:41-46, (1984).
	Perez et al., "Binding of Pt-Pentamidine to Nucleosomal DNA. Studies of the Antiproliferative Activity of the Drug Against Human Cancer Cells", *Chemico-Biological Interactions*, 89:61-72, (1993).
	Perez et al., "DNA Binding Properties and Antileukemic (L1210) Activity of A Pt-Pentamidine Complex", *Chem. Biol. Interactions*, 77:341-355, (1991).
	Ramanathan et al., "Determination of the Antifilarial Drug UMF-078 and its Metabolites UMF-060 and Flubendazole in Whole Blood Using High-Performance Liquid Chromatography", *J. Chromatogr. B Biomed. Appl*, 655:269-273 (1994).
	Reddy et al., "Synthetic DNA Minor Groove-Binding Drugs", *Pharmacology & Therapeutics*, 84:1-111, (1999).
	Redondo et al., "Influence of Surfactants on Oral Bioavailability of Albendazole Based on the Formation of the Sulphoxide Metabolites in Rats", *Biopharm. Drug Dispos.*, 19:65-70 (1998).
	Rolin et al., "Study of the In Vitro Bioactivation of Albendazole in Human Liver Microsomes and Hepatoma Cell Lines", *Cell Biol. Toxicol.* 5:1-14 (1998).

EXAMINER CM	DATE CONSIDERED 8-9-04

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50164/005002
	Serial No.	Not Yet Assigned
	Applicant	Borisy et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Filing Date	October 2, 2003
	Group	Not Yet Assigned
(37 C.F.R. § 1.98(b))	IDS Filed	October 2, 2003
	Customer Number	21559

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
CM	Rosenthal et al., "Pentamidine: An inhibitor of Interleukin-1 that Acts Via a Post-Translational Event" *Toxicol. Appl. Pharmacol.* 107:555-561 (1991).
	Sands et al., "Pentamidine: A Review", *Reviews of Infectious Diseases*, 7:625-634, (1985).
	Sansom et al., "Structural Studies on Bio-Active Compounds. Part XIV. Molecular Modelling of the Interactions Between Pentamidine and DNA", *Anti-Cancer Drug Design*, 5:243-248, (1990).
	Schoenbach et al., "The Pharmacology, Mode of Action and Therapeutic Potentialities of Stilbamidine, Pentamidine, Propamidine and Other Aromatic Diamidines-A Review", *Medicine*, 27:327-377, (1948).
	Shapiro et al., "Selective Cleavage of Kinetoplast DNA Minicircles Promoted by Antitrypanosomal Drugs", *Proc. Natl. Acad. Sci. USA*, 87:950-954 (1990).
	Snapper, I., "Stilbamidine and Pentamidine in Multiple Myeloma", *J.A.M.A.*, 133:157-161, (1947).
	Snapper, I., "On the Influence of Stilbamidine Upon Multiple Myeloma", *Journal of the Mount Sinai Hospital*, 8:119-127, (1946).
	Tidwell et al., "Analogues of 1,5-Bis(4-amidinophenoxy)pentane (Pentamidine) in the Treatment of Experimental *Pneumocystis carinii* Pneumonia", *J. Med. Chem.* 33:1252-1257 (1990).
	Turner et al., "The Mutagenic Properties of DNA Minor-Groove Binding Ligands", *Mutation Research*, 355:141-169, (1996).
	Van Wauwe et al., "The Inhibitory Effect of Pentamidine on the Production of Chemotactic Cytokines by In Vitro Stimulated Human Blood Cells", *Inflamm. Res.* 45:357-363, (1996).
	Waalkes et al., "Pentamidine Clinical Pharmacologic Correlations In Man and Mice", *Clinical Pharmacology & Therapeutics*, 11:505-512, (1970).
	Whittaker et al., "Effects of Benzimidazole Analogs on Cultures of Differentiating Rodent Embryonic Cells", *Toxicol. Appl. Pharmacol.* 113:144-151 (1992).
✓	Zakrzewska et al., "The Solvation Contribution to the Binding Energy of DNA with Non-Intercalating Antibiotics", *Nucleic Acids Res.* 12:6559-6574 (1984).

EXAMINER CM	DATE CONSIDERED 8-9-04

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

OIPE JC37
JUL 22 2004
PATENT & TRADEMARK OFFICE

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50164/005002
	Serial No.	10/677,664
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant	Alexis Borisy et al.
	Filing Date	October 2, 2003
	Group	1614
(37 C.F.R. § 1.98(b))	IDS Filed	July 20, 2004
	Customer No.	21559

U.S. PATENT DOCUMENTS

Examiner's Initials	Patent Number	Publication or Issue Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	5,770,593 A	06/23/98	Grunicke et al.			
	6,569,853 B1	05/27/03	Borisy et al.			
	~~2002/0165261~~ 6,613,125	~~11/07/02~~	Borisy			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 2004/06849	1/22/2004	W.I.P.O.			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

	Deger et al., "A New Therapeutic Approach for the Treatment of Cystic Echinococosis: Percutaneous Albendazole Sulphoxide Injection without Reaspiration," Am. J. Gastroenterol. 95:248-254 (2000).
	Lacey et al., "Activity of Benzimidazole Carbamates Against L1210 Mouse Leukaemia Cells: Correlation with *In Vitro* Tubulin Polymerization Assay," Biochem. Pharmacol. 34:3603-3605 (1985).
	Makulu et al., "Effects of Pentamidine Upon Murine Leukemia and the Walker 256 Carcinoma (W256)," Am. Soc. for Pharmacol. Experimental Therapeutic," 16:105 (1974).
	Pourgholami et al., "*In Vitro* Inhibition of Human Liver Cancer Cells by Albendazole," Proceedings of the American Association for Cancer Research Annual Meeting, 41:656 (2000).
	Ram et al., "Synthesis and Biological Activity of Certain Alkyl 5-(Alkoxycarbonyl)-1H-Benzimidazole-2-Carbamates and Related Derivatives: A New Class of Potential Antineoplastic and Antifilarial Agents," J. Med. Chem., 35:539-547 (1992).

EXAMINER	DATE CONSIDERED 8-9-04

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.